Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
Cost of A Private Drug Plan Claim
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.
Canadian Drug Access Pathway
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
Cost Drivers: Analysis of Private Drug Plans in Canada 2021
The 2021 Cost Drivers report highlights the consistent annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
2016-2019 Analysis of Private Drug Claim Cost Drivers
The 2016–2019 Cost Drivers report highlights annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
